{"id":103889,"date":"2019-02-22T00:00:50","date_gmt":"2019-05-17T08:54:04","guid":{"rendered":"http:\/\/www.05921.net\/index.php\/103889\/"},"modified":"2019-05-17T16:54:06","modified_gmt":"2019-05-17T08:54:06","slug":"9537713e15","status":"publish","type":"post","link":"https:\/\/www.05921.net\/index.php\/103889\/","title":{"rendered":"PD-1\/PD-L1\u6297\u4f53\u8054\u5408\u963f\u897f\u66ff\u5c3c\u4e00\u7ebf\u6cbb\u7597\u665a\u671f\u80be\u764c\u53d6\u5f97\u91cd\u5927\u7a81\u7834"},"content":{"rendered":"
\n
\n

  \u5927\u591a\u6570\u80be\u764c\u60a3\u8005\u4e3a\u80be\u900f\u660e\u7ec6\u80de\u764c\uff0c\u5176\u7531\u4e8e\u57fa\u56e0\u7a81\u53d8\u800c\u5bfc\u81f4\u8840\u7ba1\u5185\u76ae\u751f\u957f\u56e0\u5b50\uff08<\/span>VEGF<\/span>\uff09\u7684\u8fc7\u8868\u8fbe\u3002\u8212\u5c3c\u66ff\u5c3c\uff08<\/span>Sunitinib,Sutent<\/span>\uff09\u662f\u7531\u8f89\u745e\u5f00\u53d1\u7684\u4e00\u4e2a\u5c0f\u5206\u5b50\u9776\u5411\u836f\u7269\uff0c\u53ef\u6709\u6548\u6291\u5236<\/span>VEGF<\/span>\u7684\u8fc7\u8868\u8fbe\u3002\u76ee\u524d\uff0c\u8212\u5c3c\u66ff\u5c3c\u5355\u836f\u6cbb\u7597\u665a\u671f\u80be\u764c\u662f\u4e00\u7ebf\u6cbb\u7597\u6b64\u7c7b\u60a3\u8005\u7684\u91d1\u6807\u51c6\u3002\u7136\u800c\uff0c\u957f\u671f\u670d\u7528\u8212\u5c3c\u66ff\u5c3c\u7684\u60a3\u8005\u5f88\u591a\u4f1a\u4ea7\u751f\u8010\u836f\u6027\uff0c\u4ece\u800c\u5bfc\u81f4\u75be\u75c5\u7684\u6076\u5316\u3002<\/span><\/p>\n

 \u963f\u897f\u66ff\u5c3c\uff08Axitinib,Inlyta\uff09\u662f\u7531\u8f89\u745e\u5f00\u53d1\u7684\u4e00\u4e2a\u8840\u7ba1\u5185\u76ae\u751f\u957f\u56e0\u5b50\u53d7\u4f53\uff08VEGFR\uff09\u6291\u5236\u5242\uff0c\u7528\u4e8e\u6cbb\u7597\u8212\u5c3c\u66ff\u5c3c\u8010\u836f\u7684\u665a\u671f\u80be\u764c\u60a3\u8005\uff0c\u5e76\u4e14\u6bd4\u8212\u5c3c\u66ff\u5c3c\u5177\u6709\u66f4\u4f4e\u7684\u809d\u810f\u6bd2\u6027\u3002<\/span><\/p>\n

 \u8fd1\u65e5\uff0c\u5728\u65b0\u82f1\u683c\u5170\u533b\u5b66\u6742\u5fd7\uff08TheNewEngland Journal of Medicine\uff09\u4e0a\u540c\u65f6\u53d1\u8868\u4e86\u4e24\u7bc7\u6587\u7ae0\uff0c\u62a5\u9053\u4e86PD-L1\u6297\u4f53Avelumab\u548cPD-1\u6297\u4f53Pembrolizumab\u5206\u522b\u8054\u5408\u963f\u897f\u66ff\u5c3c\uff0c\u4e0e\u8212\u5c3c\u66ff\u5c3c\u5355\u836f\u6bd4\u8f83\uff0c\u4e00\u7ebf\u6cbb\u7597\u665a\u671f\u80be\u764c\u7684III\u671f\u4e34\u5e8a\u8bd5\u9a8c\u3002<\/span><\/p>\n

\"PD-1\/PD-L1\u6297\u4f53\u8054\u5408\u963f\u897f\u66ff\u5c3c\u4e00\u7ebf\u6cbb\u7597\u665a\u671f\u80be\u764c\u53d6\u5f97\u91cd\u5927\u7a81\u7834\"<\/p>\n

\u56fe1. Avelumab\u8054\u5408\u963f\u897f\u66ff\u5c3cVS\u8212\u5c3c\u66ff\u5c3c\u6cbb\u7597\u665a\u671f\u80be\u764c<\/span><\/p>\n

\"PD-1\/PD-L1\u6297\u4f53\u8054\u5408\u963f\u897f\u66ff\u5c3c\u4e00\u7ebf\u6cbb\u7597\u665a\u671f\u80be\u764c\u53d6\u5f97\u91cd\u5927\u7a81\u7834\"\u56fe2. Pembrolizumab\u8054\u5408\u963f\u897f\u66ff\u5c3cVS\u8212\u5c3c\u66ff\u5c3c\u6cbb\u7597\u665a\u671f\u80be\u764c<\/span><\/p>\n

\u5728Avelumab\u8054\u5408\u963f\u897f\u66ff\u5c3c\u4e0e\u8212\u5c3c\u66ff\u5c3c\u5355\u836f\u6bd4\u8f83\u7684III\u671f\u4e34\u5e8a\u7ed3\u679c\u4e2d\uff0c\u82e5\u4e0d\u8003\u8651PD-L1\u7684\u8868\u8fbe\u4e0e\u5426\uff0c\u5176\u4e2d\u4f4d\u65e0\u8fdb\u5c55\u751f\u5b58\u671f\uff08Progression-freeSurvival, PFS\uff09\u8054\u5408\u7ed9\u836f\u548c\u5355\u836f\u6cbb\u7597\u5206\u522b\u4e3a13.8\u4e2a\u6708\u548c8.4\u4e2a\u6708\u3002\u5ba2\u89c2\u7f13\u89e3\u7387\uff08ObjectiveResponse Rate\uff0cORR\uff09\u5206\u522b\u4e3a51.4%\u548c25.7%\u3002<\/span><\/p>\n

\u800c\u5728Pembrolizumab\u8054\u5408\u963f\u897f\u66ff\u5c3c\u4e0e\u8212\u5c3c\u66ff\u5c3c\u5355\u836f\u6bd4\u8f83\u7684III\u671f\u4e34\u5e8a\u7ed3\u679c\u4e2d\uff0c\u5176\u4e2d\u4f4d\u65e0\u8fdb\u5c55\u751f\u5b58\u671f\uff08PFS\uff09\u8054\u5408\u7ed9\u836f\u548c\u5355\u836f\u6cbb\u7597\u5206\u522b\u4e3a15.1\u4e2a\u6708\u548c11.1\u4e2a\u6708\u3002\u5ba2\u89c2\u7f13\u89e3\u7387\uff08ORR\uff09\u5206\u522b\u4e3a59.3%\u548c35.7%\u3002<\/span><\/p>\n

Table1. Comparison of Two Phase III Clinical Trials<\/span><\/p>\n\n\n\n\n\n\n
\n

Phase III \t\t\tTrial<\/span><\/p>\n<\/td>\n

\n

JAVELIN\t\t\tRenal 101 trial<\/span><\/p>\n<\/td>\n

\n

KEYNOTE-426\t\t\ttrial<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Avelumab+Axitinib<\/span><\/p>\n<\/td>\n

\n

Sunitinib<\/span><\/p>\n<\/td>\n

\n

Pembrolizumab+Axitinib<\/span><\/p>\n<\/td>\n

\n

Sunitinib<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Median PFS\t\t\t\uff08M\uff09<\/span><\/p>\n<\/td>\n

\n

13.8<\/span><\/p>\n<\/td>\n

\n

8.4<\/span><\/p>\n<\/td>\n

\n

15.1<\/span><\/p>\n<\/td>\n

\n

11.1<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

ORR\uff08%\uff09<\/span><\/p>\n<\/td>\n

\n

51.4<\/span><\/p>\n<\/td>\n

\n

25.7<\/span><\/p>\n<\/td>\n

\n

59.3<\/span><\/p>\n<\/td>\n

\n

35.7<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n


<\/p>\n

\"PD-1\/PD-L1\u6297\u4f53\u8054\u5408\u963f\u897f\u66ff\u5c3c\u4e00\u7ebf\u6cbb\u7597\u665a\u671f\u80be\u764c\u53d6\u5f97\u91cd\u5927\u7a81\u7834\"<\/p>\n

\u56fe3.Avelumab\u8054\u5408\u963f\u897f\u66ff\u5c3cVS\u8212\u5c3c\u66ff\u5c3c\u6cbb\u7597\u665a\u671f\u80be\u764c\u7684\u4e2d\u4f4dPFS<\/span><\/p>\n

\"PD-1\/PD-L1\u6297\u4f53\u8054\u5408\u963f\u897f\u66ff\u5c3c\u4e00\u7ebf\u6cbb\u7597\u665a\u671f\u80be\u764c\u53d6\u5f97\u91cd\u5927\u7a81\u7834\"<\/p>\n

\u56fe4. Pembrolizumab\u8054\u5408\u963f\u897f\u66ff\u5c3cVS\u8212\u5c3c\u66ff\u5c3c\u6cbb\u7597\u665a\u671f\u80be\u764c\u7684\u4e2d\u4f4dPFS<\/span><\/p>\n


<\/p>\n

\u4ece\u8fd9\u4e24\u4e2aIII\u671f\u4e34\u5e8a\u7684\u7ed3\u679c\u4e0a\u6765\u770b\uff0cPD-L1\u548cPD-1\u6297\u4f53\u8054\u5408\u963f\u897f\u66ff\u5c3c\u6cbb\u7597\u665a\u671f\u80be\u764c\u90fd\u8981\u663e\u8457\u4f18\u4e8e\u8212\u5c3c\u66ff\u5c3c\u5355\u836f\u6cbb\u7597\u3002\u800c\u5bf9\u4e8e\u8fd9\u4e24\u4e2a\u6297\u4f53\u4e4b\u95f4\uff0c\u7531\u4e8e\u7f3a\u4e4f\u5934\u5bf9\u5934\u7684\u6bd4\u8f83\uff0c\u6211\u4eec\u76ee\u524d\u53ea\u80fd\u8bf4\u8fd9\u4e24\u4e2a\u8054\u5408\u6cbb\u7597\u4e4b\u95f4\u7597\u6548\u4e0d\u76f8\u4e0a\u4e0b\uff0c\u5c31\u770b\u8c01\u5148\u5f97\u5230FDA\u7684\u4e0a\u5e02\u6279\u51c6\u4e86\u3002\u4f46\u662f\uff0c\u4e0d\u7ba1\u54ea\u4e2a\u5148\u88ab\u6279\u51c6\u7528\u4e8e\u4e00\u7ebf\u6cbb\u7597\u665a\u671f\u80be\u764c\uff0c\u8fd9\u5bf9\u4e8e\u60a3\u8005\u6765\u8bf4\u90fd\u662f\u91cd\u5927\u7684\u597d\u6d88\u606f\u3002<\/span><\/p>\n


<\/p>\n

\u53c2\u8003\u6587\u732e<\/span><\/p>\n

RobertJ. Motzer, et al. Avelumab plus Axitinib versus Sunitinib forAdvanced Renal- Carcinoma. New England Journal of Medicine.<\/span><\/p>\n

B.I. Rini, et al. Pembrolizumab plus Axitinib versus Sunitinib forAdvanced Renal- Carcinoma. New England Journal of Medicine.<\/span><\/p>\n

\u4f1a\u8bae\u63a8\u8350<\/span><\/strong><\/p>\n

\u5927\u5496\u9f50\u805a\u4e0a\u6d77|CAR-T\u7ec6\u80de\u6cbb\u7597\u7814\u53d1\u53ca\u751f\u4ea7\u5de5\u827a\u8bba\u575b<\/a><\/span><\/strong><\/p>\n

\u5927\u5496\u9f50\u805a\u5317\u4eac|\u56fd\u9645\u751f\u7269\u6cbb\u7597\u4ea7\u4e1a\u5927\u4f1a<\/strong><\/a><\/p>\n

2019\u7b2c\u4e09\u5c4a\u56fd\u9645\u751f\u7269\u6cbb\u7597\u5927\u4f1a\u66a8\u5c55\u89c8\u4f1a<\/strong><\/a>
<\/p>\n

\u517d\u7528\u75ab\u82d7\u4e3b\u9898\u66f4\u65b0|2019\u75ab\u82d7\u5de5\u827a\u4f18\u5316\u4e0e\u521b\u65b0\u7814\u53d1\u8bba\u575b<\/strong><\/a><\/p>\n

\u8bc6\u522b\u5fae\u4fe1\u4e8c\u7ef4\u7801\uff0c\u6dfb\u52a0\u5c0f\u7f16\uff0c\u7b26\u5408\u6761\u4ef6\u8005\u5373\u53ef\u52a0\u5165\u751f\u7269\u5236\u54c1\u5fae\u4fe1\u7fa4\uff01<\/strong><\/p>\n

\n
\n

\u8bf7\u6ce8\u660e\uff1a\u59d3\u540d+\u7814\u7a76\u65b9\u5411\uff01<\/strong><\/span><\/p>\n

\n
\n

\"PD-1\/PD-L1\u6297\u4f53\u8054\u5408\u963f\u897f\u66ff\u5c3c\u4e00\u7ebf\u6cbb\u7597\u665a\u671f\u80be\u764c\u53d6\u5f97\u91cd\u5927\u7a81\u7834\"<\/p>\n

\"PD-1\/PD-L1\u6297\u4f53\u8054\u5408\u963f\u897f\u66ff\u5c3c\u4e00\u7ebf\u6cbb\u7597\u665a\u671f\u80be\u764c\u53d6\u5f97\u91cd\u5927\u7a81\u7834\"
<\/p>\n<\/section>\n<\/section>\n

\n
\n
\n
\n
\n
\n

<\/section>\n<\/section>\n<\/section>\n<\/section>\n
\n
\n
\n
<\/section>\n
<\/section>\n<\/section>\n
\n
\n
\u7248<\/section>\n<\/section>\n
\n
\u6743<\/section>\n<\/section>\n
\n
\u58f0<\/section>\n<\/section>\n
\n
\u660e<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

\u7248\u6743\u4e3a\u6240\u6709\u3002\u6b22\u8fce\u4e2a\u4eba\u8f6c\u53d1\u5206\u4eab\u3002\u5176\u4ed6\u4efb\u4f55\u5a92\u4f53\u3001\u7f51\u7ad9\u5982\u9700\u8f6c\u8f7d\u6216\u5f15\u7528\u672c\u7f51\u7248\u6743\u6240\u6709\u5185\u5bb9\u987b\u83b7\u5f97\u6388\u6743\u4e14\u5728\u9192\u76ee\u4f4d\u7f6e\u5904\u6ce8\u660e\u201c\u8f6c\u81ea\uff1a\u201d\u3002<\/span>
<\/p>\n

\"PD-1\/PD-L1\u6297\u4f53\u8054\u5408\u963f\u897f\u66ff\u5c3c\u4e00\u7ebf\u6cbb\u7597\u665a\u671f\u80be\u764c\u53d6\u5f97\u91cd\u5927\u7a81\u7834\"<\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section><\/div>\n","protected":false},"excerpt":{"rendered":"

  \u5927\u591a\u6570\u80be\u764c\u60a3\u8005\u4e3a\u80be\u900f\u660e\u7ec6\u80de\u764c\uff0c\u5176\u7531\u4e8e\u57fa\u56e0\u7a81\u53d8\u800c\u5bfc\u81f4\u8840\u7ba1\u5185\u76ae\u751f\u957f\u56e0\u5b50\uff08VEGF\uff09\u7684\u8fc7\u8868\u8fbe\u3002\u8212\u5c3c\u66ff\u5c3c […]<\/p>\n","protected":false},"author":1,"featured_media":103890,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[1],"tags":[],"_links":{"self":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts\/103889"}],"collection":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/comments?post=103889"}],"version-history":[{"count":1,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts\/103889\/revisions"}],"predecessor-version":[{"id":103898,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts\/103889\/revisions\/103898"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/media\/103890"}],"wp:attachment":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/media?parent=103889"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/categories?post=103889"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/tags?post=103889"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}